Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PNV-21
- Development stage
- Unknown
- Lead developer
- Fred Hutchinson Cancer Center
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PNV-21 is a novel personalized neoantigen vaccine composed of up to 20 neoantigen peptides, identified from whole-exome and RNA sequencing of each patient's tumor. It is being investigated for the treatment of PD-1 inhibitor-refractory metastatic melanoma. The vaccine is administered intramuscularly in combination with intravenous nivolumab and the adjuvant Poly-ICLC. It aims to induce anti-tumor immune activation by targeting cancer-specific neoantigens.
- Other names
- personalized multi-peptide neo-antigen vaccinepersonalized neo-antigen peptide vaccinepersonalized neoantigen peptide vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on PNV-21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PNV-21.